The Gut-Brain Axis: How Peptides Connect Gut and Mind

The vagus nerve (cranial nerve X) is the primary neural conduit between the gut and the brain, carrying approximately 80% afferent (gut-to-brain) and 20% efferent (brain-to-gut) fibres.

Afferent signalling (gut → brain): - Vagal afferents detect mechanical stretch, chemical signals, and hormonal messages from the gut - These signals reach the nucleus tractus solitarius (NTS) in the brainstem - From the NTS, information is relayed to higher brain centres including the hypothalamus, amygdala, and prefrontal cortex - This pathway mediates satiety signals, nausea, and visceral pain perception

Efferent signalling (brain → gut): - Vagal efferents regulate gastric acid secretion, gut motility, and intestinal permeability - The "cholinergic anti-inflammatory pathway" — vagal acetylcholine release suppresses intestinal inflammation - Stress-induced vagal withdrawal can increase gut permeability ("leaky gut")

The vagal tone concept: - Higher vagal tone (measured by heart rate variability) is associated with better gut function, lower inflammation, and improved emotional regulation - Chronic stress reduces vagal tone, potentially disrupting gut-brain communication - Several peptides appear to influence vagal signalling, which may partly explain their gut-brain effects

The enteric nervous system (ENS) contains approximately 500 million neurones — more than the spinal cord — earning it the designation "second brain."

ENS architecture: - Myenteric plexus (Auerbach's): Located between the longitudinal and circular muscle layers, primarily controls gut motility - Submucosal plexus (Meissner's): Located in the submucosa, regulates secretion, blood flow, and absorption

Neurotransmitters shared between gut and brain: - Serotonin (5-HT): Approximately 95% of the body's serotonin is produced in the gut by enterochromaffin cells - Dopamine: Significant enteric production — gut dopamine influences motility and secretion - GABA: Present in the ENS, modulates gut motility and visceral sensitivity - Acetylcholine: The primary excitatory neurotransmitter in the ENS

Gut peptides as neurotransmitters: - VIP (vasoactive intestinal peptide) relaxes smooth muscle and increases secretion - Substance P mediates pain signalling and inflammation - GLP-1 and PYY act as both hormones and local neuromodulators - Cholecystokinin (CCK) triggers satiety and digestive enzyme release

The ENS can function independently of the central nervous system, coordinating digestion autonomously. However, it is in constant communication with the brain through vagal, sympathetic, and hormonal pathways.

GLP-1 (glucagon-like peptide-1) is a prime example of a gut-brain peptide, and semaglutide's effects illustrate the axis in action.

GLP-1 in the gut: - Secreted by intestinal L-cells in response to nutrients - Stimulates insulin secretion, slows gastric emptying, and suppresses glucagon - Activates vagal afferents to signal satiety to the brain

GLP-1 in the brain: - GLP-1 receptors are expressed in the hypothalamus, brainstem, hippocampus, and cortex - Central GLP-1 signalling reduces appetite, food reward, and possibly food-related cravings - GLP-1 receptor agonists show neuroprotective properties in preclinical models - Brain effects may explain semaglutide's impact on food-related behaviours beyond simple appetite suppression

Semaglutide's gut-brain effects: - Profound appetite reduction likely involves both peripheral (vagal) and central (brain GLP-1R) mechanisms - Reports of reduced alcohol and nicotine cravings are being investigated — possibly through reward pathway modulation - Nausea side effect is vagally mediated — the gut signals "fullness" or "discomfort" to the brainstem - Delayed gastric emptying is both a therapeutic mechanism (prolonged satiety) and a side effect source (nausea, reflux)

Semaglutide trials for Alzheimer's disease (EVOKE programme) represent a direct test of whether GLP-1 receptor agonism has clinically meaningful brain effects.

BPC-157, derived from a protein found in human gastric juice, has been researched for effects that span both the gut and the brain:

Gut-specific effects (animal studies): - Accelerates healing of gastric ulcers, intestinal anastomoses, and colonic damage - Protects against NSAID-induced gut injury - Modulates gut motility — counteracts both excessive slowing and excessive acceleration - Influences intestinal barrier integrity (tight junction proteins)

Brain-related effects (animal studies): - Counteracts behavioural effects of dopaminergic drugs - Shows protective effects in models of traumatic brain injury - Modulates serotonergic and GABAergic systems - Anxiolytic-like effects in standard rodent behavioural tests

The gut-brain connection: - BPC-157's simultaneous gut and brain effects have led researchers to hypothesise it acts partly through the gut-brain axis - Its interaction with the NO system may influence vagal signalling - Gut healing could reduce systemic inflammation, which in turn affects brain function - The dopaminergic modulation may involve enteric dopamine systems as well as central pathways

Limitations: While the dual gut-brain activity of BPC-157 is scientifically interesting, the mechanisms connecting its gut effects to brain effects remain speculative. Most BPC-157 research involves animal models, and human data is extremely limited.

Selank and the gut-brain axis: Selank, a synthetic analogue of the immunomodulatory peptide tuftsin, is primarily studied for anxiolytic and nootropic effects: - Administered intranasally, potentially accessing the CNS directly - Modulates GABA, serotonin, and dopamine systems - Immune-modulating properties may influence gut-brain communication through inflammatory pathways - Some Russian research suggests effects on intestinal immune function, though data is limited

The microbiome dimension: The gut-brain axis increasingly includes the gut microbiome as a critical intermediary: - Gut bacteria produce neurotransmitters (serotonin precursors, GABA, dopamine) - Bacterial metabolites (short-chain fatty acids) influence brain function through vagal and systemic pathways - Dysbiosis (microbial imbalance) is associated with anxiety, depression, and cognitive changes - Some peptides may indirectly affect the microbiome through their effects on gut motility, pH, and immune function

Emerging research directions: - Psychobiotics: targeting the microbiome to influence brain function - Vagus nerve stimulation as a clinical intervention for depression and inflammation - Gut-brain peptide biomarkers for neurological and psychiatric conditions - Developing peptides that specifically target gut-brain axis signalling

*This article is for educational purposes only. The gut-brain axis is a rapidly evolving field and many of the peptide interactions described are based on preclinical research. Consult a healthcare professional for any gut or brain health concerns.*